ASCO GU 2021 News : Episode 3

ASCO GU 2021 News: Dr. Petros Grivas and Dr. Arlene Siefker-Radtke

Video

Related Videos
Haeseong Park, MD, MPH
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Jennifer Brown, MD, PhD
Rebecca L. Porter, MD, PhD
Wenxin (Vincent) Xu, MD,
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Wenxin (Vincent) Xu, MD,
Jennifer Brown, MD, PhD
Wenxin (Vincent) Xu, MD
Anthony D'Amico MD, PhD
Related Content
Andrew Hantel, MD, faculty member, Divisions of Leukemia and Population Sciences, Dana-Farber Cancer Institute

Study Provides a First Look at Oncologists' Views on Ethical Implications of AI in Cancer Care

April 19th 2024
Article
Andrew J. Wagner, MD, PhD, medical director, Ambulatory Oncology, senior physician, Dana-Faber Cancer Institute; associate professor, medicine, Harvard Medical School

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

March 28th 2024
Podcast
Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

April 17th 2024
Article
Matthew S. Davids, MD, MMSc

FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL

January 25th 2024
Podcast
Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center

Insider Insights: Unveiling Takeaways from AACR 2024

April 11th 2024
Article
Neuro-Inclusive Oncology Care and Empowerment Program

Neuro-Inclusive Oncology Care and Empowerment Program

April 8th 2024
Article